Kasaragod: Clash erupts after BJP men prevent IUML activists from voting

Bengaluru, May 11: Karnataka Chief Minister BS Yediyurappa on Monday inaugurated four buses that have been converted into COVID-19 testing facilities in Bengaluru.

State Deputy Chief Minister C N Ashwath Narayan, Karnataka Revenue Minister R Ashoka and Member of Parliament from Bengaluru South Tejasvi Surya were also present.

"The mobile fever clinic bus initiative was taken by Sanchit Gaurav, Founder and CEO of Housejoy, in association with the Government of Karnataka, the Karnataka State Road Transport Corporation (KSRTC), MP Tejaswi Surya, other partners, to increase the number of COVID tests across Bengaluru and win the fight against the virus," said KSRTC in a statement.

The bus is divided into two zones with beds and a consultation area, maintaining proper hygiene conditions.

The KSRTC said there will be four teams with four mobile bus clinics across Bengaluru - each team comprising of one doctor, three nurses and one lab technician with several volunteers facilitating the process.

The teams will be starting from red zones and will try to screen the maximum number of residents from these zones for symptoms and quarantine those who test positive.

"The testing process will start by providing free glucose, blood pressure test and COVID-19 symptoms consultation for all residents," KSRTC added.

If anyone showcases any COVID-19 symptoms, their swab will be collected immediately for testing by Biognosys Technologies (ICMR certified).

Further, the information will be provided to the government and place the person under quarantine.

"KSRTC has already initiated this mobile fever clinic buses with the association of the District Administration in Mysuru, Mandya, Tumkur, Mangaluru, Bagalkote, Hubli, Belagavi, Bengaluru and Raichur," it said.

According to the KSRTC on April 25, the cost of this clinic construction on a bus is Rs 50,000.

Mangaluru,  May 3: An unidentified vehicle mowed down a 62-year-old security guard near Guruvayanakere, Belthangady taluk, on Saturday.

The deceased Lingappa Moolya was returning to his home in Guruvayanakere on a two-wheeler when the hit-and-run case took place. Police said he was hit by a truck. A guard at an ATM, Moolya was also an active member of the local Kulala Association.

A case was registered at Belthangady police station.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.